|
Tattoos, Cellulite and One of the Wealthiest Families in the US. |
|
When investors, especially small cap investors, discover a low float stock that has exciting news, they can quickly move into it like a swarm of bees. |
|
For those of you who don't know what a "float" is, it's the actual shares that are able to be traded in a public company. |
|
When you buy shares of any public company, you are buying a piece of the "float." |
|
A "low float" stock just means that there are relatively few shares available to be bought or sold. |
|
When this happens, you can see parabolic moves either up or down like we recently saw with Bio-Path Holdings (Nasdaq: BPTH), when the stock went from $2 per share to $73.52 in just 6 days. |
|
Investors are constantly looking for these types of plays and we think that we've found what could be the next possible candidate. |
|
The company very quietly just completed their IPO on the Nasdaq and they only have around 2.2 million shares (BPTH had less than 1M shares in their float) ) that were sold in the IPO that are available to be traded, which would be considered a "low float" compared to a stock like Apple which has over 4.4 billion shares in their float. |
|
Click here to find out the Stock Symbol and to read our In-Depth Report on this company. | |
They are a medical device company that is currently focusing on 3 different areas such as cellulite reduction, tattoo removal and subcutaneous fat reduction. |
|
Besides being a low float stock, here are some corporate highlights that stood out to us: - Their breakthrough acoustic shockwave device is currently being used in a collaborative trial with a multibillion-dollar, global aesthetics company
- They're majority owned by a member of one of the richest families in the world
- Their shockwave device recently won the "Best in Session" award given by the prestigious American Society for Laser Medicine & Surgery
- Their device originated at the MD Anderson Cancer Center, the world's largest research center, and they remain a shareholder of the company today
- Executive and science advisory teams, as well as their board of directors, are comprised of aesthetic and medical device experts, including senior management from the makers of CoolSculpting (the leading non-surgical fat reduction technology that was acquired by Allergan for $2.4B [$56 per share]).
|
|
Click here to find out the Stock Symbol and to read our In-Depth Report on this company. |
|